Regulation of Angiogenesis in Limb Arterial Injury (Experimental Investigation)

Introduction. In the modern armed conflict, limb injuries have a high proportion in the structure of combat surgical pathology. In this case, injuries to the arteries of the limbs are often accompanied by massive external bleeding and/or acute ischemia, which is one of the main causes of death. The use of adjuvant therapeutic stimulation of angiogenesis in combat vascular pathology seems promising. Objective. To investigate the influence and dynamics of angiogenesis regulation and determine the role of VEGF in the pathogenesis of limb artery injuries in an experimental model of acute hind limb ischemia (AHLI) in laboratory animals.
Materials and methods. An experimental model of acute hind limb ischemia (AHLI) was developed, dynamic observation and evaluation of the effect of drug-induced angiogenesis and systemic administration of antiangiogenic antibodies in laboratory animals (male White Giant rabbits) of one batch weighing 3673±113 g (n=36).
Results. In Group Ia (drug-induced angiogenesis), there was a long-term positive survival rate of up to 24 days of the experimental study, in contrast to the other 3 groups. The survival data in Group Ia correlates with the quantitative determination of VEGF in blood serum, which by day 30 is 87.08±2.44 pg/ml (p<0.001). By 30 day of the experimental study, the level of tissue perfusion after ligation of the femoral artery was 81.75±4.2% (p<0.05).
Conclusions. Gene and cellular technologies can become one of the most important methods for restoring perfusion in ischemic tissues due to the formation and growth of the microvascular network, which subsequently significantly reduces the number of amputations performed and improves the final result of treatment for this pathology. The results obtained indicate the effectiveness of adjuvant stimulation of angiogenesis, which also affected the survival of laboratory animals.

1. Klinkov RR, Eroshkin IA, Vasil’ev DYU, Moskalenko VA. Treatment of critical lower limb ischemia - current trends (literature review). Diagnostic and Interventional Radiology. 2022;16(2);6-53. (In Russ.). https://doi.org/10.25512/DIR.2022.16.2.05.

2. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circulation Research. 2009;105(8):724-736. https://doi.org/10.1161/circresaha.109.200386.

3. Makarevich Pl, Shevelev AYa, Rybalkin IN, et al. Novel plasmid constructs with angiogenic growth factors genes human VEGF, HGF and angiopoietin-1 for therapeutic angiogenesis. Cell Transplantology and Tissue Engineering. 2010;5(1):47-52. (In Russ.).

4. Shyu KG., Chang Н, Wang BW, Kuan Р. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. The American Journal of Medicine. 2003;114(2):85-92. https://doi.org/10.1016/s0002-9343(02)01392-x.

5. Birk DM, Barbato J, Mureebe L, Chaer RA. Current insights on the biology and clinical aspects of VEGF regulation. Vascular and Endovascular Surgery. 2008; 42(6):517-530. https://doi.org/10.1177/1538574408322755.

6. Grochot-Przeczek A, Dulak J, Jozkowicz A. Therapeutic angiogenesis for revascularization in peripheral artery disease. Gene. 2013;525(2):220–228. https://doi.org/10.1016/j.gene.2013.03.097.

7. Pan T, Wei Z, Fang Y, Dong Z, Fu W. Therapeutic efficacy of CD34(+) cell-involved mononuclear cell therapy for nooption critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Vascular Medicine. 2018;23(3):219-231. https://doi.org/10.1177/1358863x17752556.

8. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. Journal of Biochemistry. 2013;153(1):13-19. https://doi.org/1093/jb/mvs136.

9. Melincovici CS, Bosca AB, Susman S, Marginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Romanian Journal of Morpholgy & Embryology. 2018;59(2):455–467. PMID: 30173249.

10. Shibuya M. VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases. Endocrine, Metabolic & Immune Disorders - Drug Targets. 2015;15(2):135-144. https://doi.org/10.2174/1871530315666150316121956.

11. Slobodkina E, Boldyreva M, Karagyaur M, Eremichev R, Alexandrushkina N, Balabanyan V, et al. Therapeutic angiogenesis by a “Dynamic Duo”: simultaneous expression of HGF and VEGF165 by novel bicistronic plasmid restores blood flow in ischemic skeletal muscle. Pharmaceutics. 2020;12(12):1231. https://doi.org/10.3390/pharmaceutics12121231.

12. Yudin MA, Plaksa IL, Mzhavanadze ND, et al. Estimation of systemic distribution and angiogenic effect of pl-VEGF165 in the model of limb ischemia. Circulatory pathology and cardiac surgery. 2015; 19(4-2):33-42. (In Russ.). https://doi.org/10.21688/1681-3472-2015-4-2-33-42.

13. Barc P, Antkiewicz M, Sliwa B, Fraczkowska K, Guzinski M, Dawiskiba T, et al. Double VEGF/HGF gene therapy in critical limb ischemia complicated by diabetes mellitus. Journal of Cardiovascular Translational Research. 2021 Jun;14(3):409-415. https://doi.org/10.1007/s12265-020-10066-9.

14. Liu Y, Li J, Zhou J, Liu X, Li H, Lu Y, et al. Angiogenesis and functional vessel formation induced by interstitial flow and vascular endothelial growth factor using a microfluidic chip. micromachines (Basel). 2022 Jan 29;13(2):225. https://doi.org/10.3390/mi13020225.

15. Tokunaga N, Nagaya N, Shirai M, Tanaka E, Ishibashi-Ueda H, Harada-Shiba M, et al. Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: benefits of a novel nonviral vector, gelatin. Circulation. 2004;109(4):526-531. https://doi.org/10.1161/01.CIR.0000109700.81266.32.

16. Laguens R, Cabeza Meckert P, Vera Janavel G, Del Valle H, Lascano E, Negroni J, et al. Entrance in mitosis of adult cardiomyocytes in ischemic pig hearts after plasmid-mediated rhVEGF165 gene transfer. Gene Ther. 2002;9(24):1676-1681. https://doi.org/10.1038/sj.gt.3301844.